Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,accountsPayable,otherCurrentLiab,otherLiab,longTermDebt,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,netBorrowings,repurchaseOfStock,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsForward,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,DYN,478260000.0,51205900,18625000,,-24968000,,-24968000,6509000,0,-25134000,-25134000,,,,,,0,0,25134000,0,166000,,-24968000,-24968000,582473000.0,13450000.0,478260000.0,491710000.0,6000.0,-104151000.0,-68000.0,2303000.0,310949000.0,13450000.0,-68000.0,2339000.0,487068000.0,172136000.0,5760000.0,,,,-128366000.0,1869000.0,-128375000.0,157250000.0,331000.0,157250000.0,10482000.0,-18393000.0,238000.0,4137000.0,-9000.0,,,,473618000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,16.48,1630503055,-0.45000076,17.02,17.02,16.48,1253,USD,NMS,843873216,-14400000,False,False,REGULAR,2,-2.658008,16.48 - 17.02,us_market,0,"Dyne Therapeutics, Inc.",16.93,16.86,17.01,8,8,finmb_608699906,NasdaqGS,"Dyne Therapeutics, Inc.",USD,253837,242516,2.9799995,0.2207407,13.5 - 32.315,-15.834999,-0.4900201,13.5,32.315,1620298740,1620298740,1620298740,-0.38,-2.41,-6.838174,18.017221,-1.5372219,-0.085319586,18.22826,-1.7482605,-0.09590935,-43.36842,15,America/New_York,EDT,,,,32.31,13.5,18.02,18.23,253.84k,242.52k,51.21M,,17.58M,2.90%,98.44%,1.84M,9.57,6.19%,3.58%,1.77M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-18.78%,-31.09%,,,,,-75.14M,-76.52M,,,483.08M,9.43,596k,0.12,36.21,,-57.61M,-36.25M,Value,02451,Healthcare,56,9,3,"Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.",Waltham,781 786 8230,MA,8,1609372800,1622505600,7,United States,http://www.dyne-tx.com,86400,8,830 Winter Street,781 786 8866,Biotechnology
t-1,DYN,342367000.0,51205900,22098000,,-28649000,,-28649000,6502000,0,-28600000,-28600000,,-81000.0,,,,0,0,28600000,0,-49000,,-28649000,-28649000,421572000.0,10967000.0,342367000.0,353334000.0,5000.0,-79183000.0,-27000.0,2301000.0,300852000.0,10967000.0,-27000.0,1946000.0,349087000.0,44462000.0,3440000.0,52000.0,,,-44500000.0,7453000.0,-45223000.0,-11194000.0,-3348000.0,157250000.0,-76453000.0,-20036000.0,217000.0,4227000.0,-723000.0,-10000000.0,-1060000.0,,338120000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,16.48,1630503055,-0.45000076,17.02,17.02,16.48,1253,USD,NMS,843873216,-14400000,False,False,REGULAR,2,-2.658008,16.48 - 17.02,us_market,0,"Dyne Therapeutics, Inc.",16.93,16.86,17.01,8,8,finmb_608699906,NasdaqGS,"Dyne Therapeutics, Inc.",USD,253837,242516,2.9799995,0.2207407,13.5 - 32.315,-15.834999,-0.4900201,13.5,32.315,1620298740,1620298740,1620298740,-0.38,-2.41,-6.838174,18.017221,-1.5372219,-0.085319586,18.22826,-1.7482605,-0.09590935,-43.36842,15,America/New_York,EDT,,,,32.31,13.5,18.02,18.23,253.84k,242.52k,51.21M,,17.58M,2.90%,98.44%,1.84M,9.57,6.19%,3.58%,1.77M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-18.78%,-31.09%,,,,,-75.14M,-76.52M,,,483.08M,9.43,596k,0.12,36.21,,-57.61M,-36.25M,Value,02451,Healthcare,56,9,3,"Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.",Waltham,781 786 8230,MA,8,1609372800,1622505600,7,United States,http://www.dyne-tx.com,86400,8,830 Winter Street,781 786 8866,Biotechnology
t-2,DYN,366845000.0,51205900,9679000,,-13920000,,-13920000,3841000,0,-13520000,-13520000,,-130000.0,,,,0,0,13520000,0,-400000,,-13920000,-13920000,417374000.0,14627000.0,366845000.0,381472000.0,5000.0,-50534000.0,,191000.0,379606000.0,4678000.0,,1441000.0,379840000.0,,1488000.0,573000.0,13000.0,9936000.0,-44500000.0,-608000.0,-156000.0,379963000.0,-25000.0,247478000.0,367934000.0,-11873000.0,175000.0,2505000.0,-156000.0,-13000.0,-1060000.0,-450000.0,375162000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,16.48,1630503055,-0.45000076,17.02,17.02,16.48,1253,USD,NMS,843873216,-14400000,False,False,REGULAR,2,-2.658008,16.48 - 17.02,us_market,0,"Dyne Therapeutics, Inc.",16.93,16.86,17.01,8,8,finmb_608699906,NasdaqGS,"Dyne Therapeutics, Inc.",USD,253837,242516,2.9799995,0.2207407,13.5 - 32.315,-15.834999,-0.4900201,13.5,32.315,1620298740,1620298740,1620298740,-0.38,-2.41,-6.838174,18.017221,-1.5372219,-0.085319586,18.22826,-1.7482605,-0.09590935,-43.36842,15,America/New_York,EDT,,,,32.31,13.5,18.02,18.23,253.84k,242.52k,51.21M,,17.58M,2.90%,98.44%,1.84M,9.57,6.19%,3.58%,1.77M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-18.78%,-31.09%,,,,,-75.14M,-76.52M,,,483.08M,9.43,596k,0.12,36.21,,-57.61M,-36.25M,Value,02451,Healthcare,56,9,3,"Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.",Waltham,781 786 8230,MA,8,1609372800,1622505600,7,United States,http://www.dyne-tx.com,86400,8,830 Winter Street,781 786 8866,Biotechnology
t-3,DYN,-13393000.0,51205900,6089000,,-7886000,,-7886000,1764000,0,-7853000,-7853000,,-57000.0,,,,0,0,7853000,0,-123000,,-7886000,-7886000,6493000.0,14290000.0,-13393000.0,13571000.0,1000.0,-36614000.0,,191000.0,11672000.0,4134000.0,,1499000.0,11881000.0,,2192000.0,82000.0,207000.0,9949000.0,-44500000.0,501000.0,-211000.0,11908000.0,-129000.0,247478000.0,4409000.0,-7288000.0,150000.0,64000.0,-211000.0,9936000.0,-1060000.0,-450000.0,7747000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,16.48,1630503055,-0.45000076,17.02,17.02,16.48,1253,USD,NMS,843873216,-14400000,False,False,REGULAR,2,-2.658008,16.48 - 17.02,us_market,0,"Dyne Therapeutics, Inc.",16.93,16.86,17.01,8,8,finmb_608699906,NasdaqGS,"Dyne Therapeutics, Inc.",USD,253837,242516,2.9799995,0.2207407,13.5 - 32.315,-15.834999,-0.4900201,13.5,32.315,1620298740,1620298740,1620298740,-0.38,-2.41,-6.838174,18.017221,-1.5372219,-0.085319586,18.22826,-1.7482605,-0.09590935,-43.36842,15,America/New_York,EDT,,,,32.31,13.5,18.02,18.23,253.84k,242.52k,51.21M,,17.58M,2.90%,98.44%,1.84M,9.57,6.19%,3.58%,1.77M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-18.78%,-31.09%,,,,,-75.14M,-76.52M,,,483.08M,9.43,596k,0.12,36.21,,-57.61M,-36.25M,Value,02451,Healthcare,56,9,3,"Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.",Waltham,781 786 8230,MA,8,1609372800,1622505600,7,United States,http://www.dyne-tx.com,86400,8,830 Winter Street,781 786 8866,Biotechnology
